跳至主要内容
临床试验/JPRN-jRCT2031210315
JPRN-jRCT2031210315暂停2 期

[M20-370] A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment

Yamazaki Hayato0 个研究点目标入组 160 人开始时间: 2021年9月15日最近更新:
适应症

试验速览

阶段
2 期
状态
暂停
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 50age old 至 ot applicable(—)
性别
All

入选标准

  • Clinical diagnosis of Polymyalgia Rheumatica (PMR) and fulfillment of the 2012 European League Against
  • Rheumatism/American College of Rheumatology (EULAR/ACR) provisional classification criteria for PMR.
  • - Must have had at least 2 episodes of unequivocal PMR flare.
  • - Must be on a stable dose of prednisone.
  • - Must be willing to follow the protocol-defined glucocorticoid tapering regimen.

排除标准

  • - Have been treated with a prior TNF antagonist.
  • - Current use of immunomodulators other than prednisone.

研究者

发起方
Yamazaki Hayato

相似试验